Design and Clinical Outcomes From the IMFORTE Trial | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Design and Clinical Outcomes From the IMFORTE Trial | Targeted Onc…
6 days ago
targetedonc.com
A 52-Year-Old Woman With HER2-Positive Breast Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
A 52-Year-Old Woman With HER2-Positive Breast Cancer | Targeted …
May 22, 2019
targetedonc.com
The Targeted Pulse: Explore How a Community Practice Implemented Bispecific Antibody Therapy and Key Updates in Cancer Treatments | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
The Targeted Pulse: Explore How a Community Practice Implemented …
11 months ago
targetedonc.com
Nirogacestat Shows Statistically Significant Improvements in Desmoid Tumors | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Nirogacestat Shows Statistically Significant Improvements in Desm…
Nov 28, 2023
targetedonc.com
ASH 2024 Preview for Community Oncologists: The Show and After Show | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
ASH 2024 Preview for Community Oncologists: The Show and After …
10 months ago
targetedonc.com
Amivantamab Lazertinib in EGFR-Mutated Advanced NSCLC: Results from MARIPOSA
6:53
Amivantamab Lazertinib in EGFR-Mutated Advanced NSCLC: Result…
Nov 14, 2023
targetedonc.com
FDA's July 2024 Roundup: Breakthroughs and Milestones in Cancer Treatment
FDA's July 2024 Roundup: Breakthroughs and Milestones in …
Aug 2, 2024
targetedonc.com
Findings for the Combination of Anti-TIM-3 and Anti-PD-1 in Melan…
Dec 27, 2018
targetedonc.com
Overview of MET Amplification and MET Exon 14 Skipping Mutations i…
Dec 7, 2021
targetedonc.com
KEYNOTE-091 Evaluates Adjuvant Pembrolizumab in Resected Early …
Jul 19, 2022
targetedonc.com
Phase 3 HIMALAYA Trial Shows OS Benefit of Durvalumab in HCC
Jan 18, 2023
targetedonc.com
PD-L1 Testing and Its Role in Lung Cancer Treatment Decision-Makin…
Oct 16, 2023
targetedonc.com
Characteristics of the MET Exon 14 Skipping Mutation NSCLC Populat…
Dec 1, 2021
targetedonc.com
Addressing Unmet Needs in Renal Cell Carcinoma | Targeted Oncolo…
Apr 5, 2022
targetedonc.com
Key Updates from ARMANI in Advanced HER2- Gastric/GEJ Can…
Jun 24, 2024
targetedonc.com
A Brief History of Immunotherapy
Aug 21, 2014
targetedonc.com
Treatment After Progression on Osimertinib for EGFR NSCLC | Tar…
Mar 4, 2020
targetedonc.com
Evaluating Quality of Care for Patients With Medicaid vs Private I…
Oct 5, 2022
targetedonc.com
An Introduction to Front-line Nivolumab/Ipilimumab Therapy fo…
9 months ago
targetedonc.com
Case Overview: A 67-Year-Old Man With Metastatic CSPC | Targeted …
Jun 17, 2020
targetedonc.com
Pirtobrutinib as a Game Changer for Patients With CLL
Mar 14, 2024
targetedonc.com
Defining Platinum Sensitivity vs Resistance after First-Line Treatm…
Dec 18, 2020
targetedonc.com
Key Takeaways from the OUTBACK Trial of Adjuvant Chemotherapy i…
Jul 23, 2022
targetedonc.com
Overview of phase 3 EMERALD study of elacestrant for ER , HER…
10 months ago
targetedonc.com
Lung-MAP Trial of Pembrolizumab Plus Ramucirumab Improves Over…
Aug 31, 2022
targetedonc.com
Update from KATHERINE on Adjuvant T-DM1 for Residual Inva…
Jan 11, 2024
targetedonc.com
Elacestrant Targeted Therapy for ER /HER2– Metastatic Breast Cancer: …
Jul 3, 2024
targetedonc.com
KEYNOTE-756: Pembrolizumab Plus Chemo in Early-Stage ER /HER2- …
Nov 9, 2023
targetedonc.com
2:14
Overview of Radioiodine-Refractory Differentiated Thyroid Cancer (RA…
Jan 19, 2024
targetedonc.com
Belzutifan Shows Continued Efficacy in Heavily Pretreated Adv…
Nov 4, 2022
targetedonc.com
See more videos
Static thumbnail place holder